Phase III trial comparing doxorubicin docetaxel (AT) with doxorubicin cyclophosphamide (AC) in the adjuvant treatment of high-risk node negative (pNO) and limited node positive (pN+≤53) breast cancer (BC) patients (pts):: First analysis of toxicity.

被引：0
|
作者：
Brain, EGC
Bachelot, T
Serin, D
Graïc, Y
Eymard, JC
Extra, JM
Combe, M
Nogues, C
Rouëssé, J
机构：
[1] Ctr Rene Huguenin, St Cloud, France
[2] Ctr Leon Berard, F-69373 Lyon, France
[3] Inst St Catherine, Avignon, France
[4] Ctr Henri Becquerel, F-76038 Rouen, France
[5] Inst Jean Godinot, Reims, France
[6] Inst Curie, F-75231 Paris, France
[7] Le Mans Hosp, Le Mans, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2004年 / 22卷 / 14期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
617
引用
收藏
页码：31S / 31S
页数：1
相关论文
共 50 条
  • [21] Docetaxel in Combination with Doxorubicin and Cyclophosphamide as Adjuvant Treatment for Early Node-Positive Breast Cancer in the USA: A Cost-Effectiveness and Cost-Utility Analysis
    Wolowacz, S. E.
    Seal, B. S.
    Tangirala, M.
    CANCER RESEARCH, 2009, 69 (24) : 622S - 623S
  • [22] Adjuvant dose-dense doxorubicin-cyclophosphamide versus docetaxel-doxorubicin-cyclophosphamide for high-risk breast cancer: First results of the randomised MATADOR trial (BOOG 2004-04)
    van Rossum, A. G. J.
    Kok, M.
    van Werkhoven, E.
    Opdam, M.
    Mandjes, I. A. M.
    van Leeuwen-Stok, A. E.
    van Tinteren, H.
    Imholz, A. L. T.
    Portielje, J. E. A.
    Bos, M. M. E. M.
    van Bochove, A.
    Wesseling, J.
    Rutgers, E. J.
    Linn, S. C.
    Oosterkamp, H. M.
    EUROPEAN JOURNAL OF CANCER, 2018, 102 : 40 - 48
  • [23] A phase II study of adjuvant chemotherapy with sequential doxorubicin-cyclophosphamide (AC) and docetaxel followed by radiotherapy in patients with high-risk early breast cancer. A trial of the Pakistan Cancer Research Group
    Khan, Shaharyar
    Shah, Ijaz H.
    Shahid, Abubaker
    Hafeez, Muhammed
    Perveen, Shaheena
    Javed, Abrar A.
    Masood, Ahmed I.
    ANNALS OF ONCOLOGY, 2004, 15 : 66 - 67
  • [24] Phase III randomized trial of primary chemotherapy with doxorubicin/cyclophosphamide (AC) vs docetaxel/capecitabine (TX) for stage II/III breast cancer (BC): Interim analysis.
    Lee, HG
    Lee, JJ
    Jung, KH
    Kwon, Y
    Shin, EH
    Chung, KW
    Shin, KH
    Kim, EA
    Lee, ES
    Ro, J
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 29S - 29S
  • [25] Cyclophosphamide, Epirubicin, and Fluorouracil Versus Dose-Dense Epirubicin and Cyclophosphamide Followed by Paclitaxel Versus Doxorubicin and Cyclophosphamide Followed by Paclitaxel in Node-Positive or High-Risk Node-Negative Breast Cancer
    Burnell, Margot
    Levine, Mark N.
    Chapman, Judith-Anne W.
    Bramwell, Vivien
    Gelmon, Karen
    Walley, Barbara
    Vandenberg, Ted
    Chalchal, Haji
    Albain, Kathy S.
    Perez, Edith A.
    Rugo, Hope
    Pritchard, Kathleen
    O'Brien, Patti
    Shepherd, Lois E.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (01) : 77 - 82
  • [26] Prognostic and Predictive Value of Tumor-Infiltrating Lymphocytes in a Phase III Randomized Adjuvant Breast Cancer Trial in Node-Positive Breast Cancer Comparing the Addition of Docetaxel to Doxorubicin With Doxorubicin-Based Chemotherapy: BIG 02-98
    Loi, Sherene
    Sirtaine, Nicolas
    Piette, Fanny
    Salgado, Roberto
    Viale, Giuseppe
    Van Eenoo, Francoise
    Rouas, Ghizlane
    Francis, Prudence
    Crown, John P. A.
    Hitre, Erika
    de Azambuja, Evandro
    Quinaux, Emmanuel
    Di Leo, Angelo
    Michiels, Stefan
    Piccart, Martine J.
    Sotiriou, Christos
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (07) : 860 - 867
  • [27] A phase III trial comparing full doses of epirubicin-cyclophosphamide (HEC) with intermediate doses (EC) and with CMF in the adjuvant therapy of node-positive (N+) breast cancer (BC) patients (PTS).
    Piccart, MJ
    Di Leo, A
    Beauduin, M
    Vindevoghel, A
    Michel, J
    Focan, C
    Bartholomeus, S
    Dolci, S
    Lobelle, JP
    Paesmans, M
    ANNALS OF ONCOLOGY, 2000, 11 : 17 - 17
  • [28] Randomized, phase III study of adjuvant doxorubicin plus cyclophosphamide (AC), followed by docetaxel (T) with or without capecitabine (X), in high-risk early breast cancer (EBC): efficacy results
    O'Shaughnessy, J.
    Brownstein, C.
    Hoersch, S.
    Scotto, N.
    BREAST, 2011, 20 : S65 - S65
  • [29] Prophylactic growth factor (GF) support with adjuvant docetaxel, doxorubicin, and cyclophosphamide (TAC) for node-negative breast cancer (BC):: An interim safety analysis of the GEICAM 9805 study.
    Martin, M
    Lluch, A
    Seguí, MA
    Antón, A
    Ruiz, A
    Ramos, M
    Rodríguez-Lescure, A
    Adrover, E
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 32S - 32S
  • [30] A randomized, multicenter phase III trial comparing regimens of doxorubicin plus cyclophosphamide followed by paclitaxel or doxorubicin plus paclitaxel followed by weekly paclitaxel as adjuvant therapy for patients with high risk breast cancer
    Loesch, D
    Greco, FA
    O'Shaughnessy, J
    Asmar, L
    Senzer, NN
    Burris, HA
    Hainsworth, JD
    Vukelja, S
    Sandbach, J
    Holmes, F
    Sedlacek, S
    Lindquist, D
    Pippen, J
    Olivares, J
    Boehm, KA
    Zhan, F
    Robert, N
    BREAST CANCER RESEARCH AND TREATMENT, 2004, 88 : S16 - S17
12345